EYE: ADVANCED MEDICAL OPTICS INC Profile

Ticker

Advertisement

Choose a Broker

Dynamic view of the market

U.S. Markets open in 15 hrs, 12 mins

Symbol	Value	Change	Percentage Change
DJIA	11,288.54	73.03	0.65%
NASDAQ	2,245.38	-6.08	-0.27%
S&P 500	1,262.90	1.38	0.11%

ADVANCED MEDICAL OPTICS INC

EYE

Stock price

18.71 -0.31 -1.63%

as of 01:05 PM EDT on 07/03/2008 in USD (NYSE Delay: 20 mins.)
Extended Hours

— — —

Analyst Consensus

Hold
Analyst Consensus

Strong Buy

Buy

Hold

Sell

Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: EYE

Insightful information about industries, companies, and the people who lead them.

Learn More.

2007 Sales	2007 Sales Growth	2007 Net Income	2007 Employees
$1,090,800,000	9.4%	$-192,900,000	4,100

Key Executives: EYE

Name	Title	Officer Since
James V. Mazzo	CEO	10/1/01
Richard A. Meier	COO	-
Michael J. Lambert	CFO	-
Robert F. Gallagher	Chief Accounting Officer	-
Aimee S. Weisner	General Counsel	-
Douglas H. Post	Executive VP	-
Holger Heidrich, Ph.D.	Vice President	-
Jane E. Rady	Executive VP, Divisional	-

View All Key Executives

Jane E. Rady, 59, has been our Executive Vice President, Strategy and Corporate Development, since February 2007. From April 2006 to February 2007, she was our Corporate Vice President, Strategic and Corporate Development, and from April 2002 to April 2006, she was our Corporate Vice President, Strategy and Technology. Prior to joining us, Ms. Rady was a director and the Chief Executive Officer of Integrated Genomics, Inc. and was a consultant to... View Full Profile

Jane E. Rady

Ms. Neff is the President and Chief Executive Officer of Pathwork Diagnostics, Inc. (formerly Predicant Biosciences, Inc. and Biospect, Inc.), which she joined in 2003. Pathwork is focused on applying genomics to unmet clinical needs in oncology. Prior to joining Pathwork, from 1988 to 2003, Ms. Neff held a number of executive positions at Becton Dickinson and Company, a $4 billion global medical technology and device company. Most recently, from... View Full Profile

Deborah J. Neff

Sheree L. Aronson, 52, has been our Corporate Vice President, Corporate Communications, Investor Relations and Market Research, since September 2006, and served as our Vice President, Corporate Communications and Investor Relations from August 2003 to September 2006. From August 2002 to July 2003, she was Director of Communications for RSM EquiCo, a division of H&R Block, and from August 1999 to July 2002, she was a Senior Vice President at... View Full Profile

Sheree L. Aronson

Francine D. Meza, 50, was appointed Corporate Vice President, Human Resources in September 2006, and from June 2002 to September 2006, she was our Senior Vice President, Human Resources. From 1984 through our spin-off in June 2002, Ms. Meza served in various human resources positions at Allergan and its acquired business, American Medical Optics. Prior to the spin-off, Ms. Meza was the Vice President, Human Resources for worldwide operations at... View Full Profile

Francine D. Meza

Ms. Davila is a retired executive and the former Chairman of the Board of Directors and Chief Executive Officer of VISX, Incorporated, which we acquired in May 2005. Ms. Davila served on the VISX Board of Directors from 1995 to 2005, and served as its Chairman and Chief Executive Officer from 2001 to 2005. From 1995 to 2001, Ms. Davila held a number of positions at VISX, including Executive Vice President, President, and Chief Operating Officer.... View Full Profile

Elizabeth H. Davila

Leonard R. Borrmann, Pharm.D., 50, has been our Executive Vice President, Research and Development, since February 2007, was Corporate Vice President, Research and Development, from September 2006 to February 2007, was Senior Vice President, Research and Development, from July 2005 to September 2006, and was our Vice President, Surgical Research and Business Development, from March 2004 to June 2005. From August 2002 to February 2004, Dr.... View Full Profile

Dr. Leonard R. Borrmann, Pharm.D.

Aimee S. Weisner, 39, is our Executive Vice President, Administration, and Secretary, a position she assumed in February 2008. Her responsibilities include Legal Affairs, Compliance and Human Resources, and she is our Chief Ethics Officer. From February 2007 to February 2008, she served as Executive Vice President, Administration, General Counsel and Secretary. From our inception through February 2007, her title was Corporate Vice President,... View Full Profile

Aimee S. Weisner

C. Russell Trenary, III, 50, was appointed Executive Vice President, Global Public Policy and Medical Education in October 2007. From February thru October 2007, he was Executive Vice President and President, Cataract Refractive Group, in February 2007. From November 2006 to February 2007, Mr. Trenary was our Corporate Vice President and President, Cataract Refractive Surgery Group, and from February 2004 to November 2006, he was our Corporate... View Full Profile

C. Russell Trenary, III

Holger Heidrich, Ph.D., 55, is our Corporate Vice President and President, EAM and International Government Affairs, a position he assumed in February 2007, and was Corporate Vice President and President, EAM Refractive Vision Correction, from November 2006 to February 2007. From July 2005 to November 2006, Dr. Heidrich was our Corporate Vice President and President, Cataract / Implant Business, from December 2003 through July 2005, he served as... View Full Profile

Holger Heidrich, Ph.D.

Mr. Mazzo is our Chairman of the Board and Chief Executive Officer. He has been a member of our Board of Directors since October 2001. Mr. Mazzo has been Chief Executive Officer since our inception and was President from inception until November 2007. Mr. Mazzo became Chairman of the Board in May 2006. Prior to AMO"s spin-off from Allergan in 2002, Mr. Mazzo served in various positions at Allergan, most recently as Allergan"s Corporate Vice... View Full Profile

James V. Mazzo

Mr. Mussallem is the Chairman of the Board and Chief Executive Officer of Edwards Lifesciences Corporation, a position he has held since 2000, when Edwards Lifesciences was spun off from Baxter International, Inc. Edwards Lifesciences is a medical device company focused on cardiovascular disease treatments. Prior to 2000, Mr. Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior... View Full Profile

Michael A. Mussallem

Richard A. Meier, 48, was appointed President and Chief Operating Officer in November 2007, and from February 2007 was Chief Operating Officer and Chief Financial Officer. He previously served as our Executive Vice President, Operations, President, Eye Care Business, and Chief Financial Officer from April 2006 to February 2007. From February 2004 to April 2006, he was our Executive Vice President of Operations and Finance and Chief Financial... View Full Profile

Richard A. Meier

Robert F. Gallagher, 49, is our Senior Vice President, Chief Accounting Officer and Controller, a position he assumed in April 2006, and he was our Vice President, Controller from February 2002 to April 2006. Mr. Gallagher has over 18 years of financial management experience in our industry. From 1995 to 2001, he served in a variety of senior financial positions at Bausch & Lomb and its acquired business, Chiron Vision, most recently as Vice... View Full Profile

Robert F. Gallagher

Dr. Link is Managing Director and a co-founder of Versant Ventures, a venture capital firm located in Newport Beach, California investing in early-stage health care companies. Prior to co-founding Versant Ventures in 1999, Dr. Link was a general partner at Brentwood Venture Capital, where he invested in a number of early-stage companies. From 1986 to 1997, Dr. Link was Chairman and Chief Executive Officer of Chiron Vision, a subsidiary of Chiron... View Full Profile

Dr. William J. Link, Ph.D.

Mr. Chavez is President of Advanced Neuromodulation Systems (ANS), a position he has held since he joined ANS in April 1998 and which he continues to hold following the acquisition of ANS by St. Jude Medical, Inc. in November 2005. From April 1998 to November 2005, Mr. Chavez was also Chief Executive Officer and a Director of ANS. ANS is a medical device company focused on neurostimulation and drug pump technologies. Prior to joining ANS, Mr.... View Full Profile

Christopher G. Chavez

Angelo Rago, 44, has been our Senior Vice President, Global Customer Services, since February 2007, and served as our Vice President, Customer Support, from June 2005 to February 2007. Mr. Rago joined us after a 17 year career with Siemens Medical, where he held a number of senior management positions in both the service and product development areas. From November 2001 to June 2005, Mr. Rago was Vice President of Global Customer Services for the... View Full Profile

Angelo Rago

Mr. Rollans is the Presiding Director of our Board of Directors. Mr. Rollans retired in 2003 from the Board of Directors of Fluor Corporation and from his position as Fluor"s Group Executive of Investor Relations and Corporate Communications, in which he was responsible for leading the company"s external affairs, including Investor Relations, Corporate Communications, Community and Government Relations functions. Prior to assuming that role in... View Full Profile

James O. Rollans

Mr. Palmisano is the President, Chief Executive Officer, and a member of the board of directors of ev3 Inc., a global endovascular device company, a position he assumed in April 2008. From November 2007 to April 2008, he was a Venture Partner with SV Life Sciences Advisors, a venture capital advisor and manager making investments in the human life sciences sector. Mr. Palmisano joined SV Life Sciences in November 2007. Prior to that, he was the... View Full Profile

Robert J. Palmisano

Douglas H. Post, 56, has been our Executive Vice President, and President, Corneal Refractive Group, since February 2007, and from November 2006 to February 2007, he was our Corporate Vice President and President, Corneal Refractive Surgery Group. From July 2005 to November 2006, Mr. Post served as our Corporate Vice President and President, Laser Vision Correction Business. From May 2005 to July 2005, Mr. Post was our Region President of the... View Full Profile

Douglas H. Post

Mr. Morfit is a Partner of ValueAct Capital, a private investment partnership and a significant AMO stockholder. Prior to joining ValueAct Capital in January 2001, Mr. Morfit worked in equity research for Credit Suisse First Boston for more than two years. He supported the senior healthcare services analyst, covering fifteen companies in the managed care and physician services industries. Mr. Morfit is a director of Valeant Pharmaceuticals... View Full Profile

G. Mason Morfit

Mr. Heinrich has been the Senior Vice President"Chief Financial Officer of Clorox Co. since July 2004. He joined Clorox in March 2001 as vice president"Controller. He was elected Vice President"Chief Financial Officer in October 2003. From October 1996 through February 2001, he was employed by Transamerica Finance Corporation. Prior to that he was employed by Granite Management Corporation, an indirect subsidiary of Ford Motor Company, as Senior... View Full Profile

Daniel J. Heinrich, CPA

Michael J. Lambert, 46, joined AMO as our executive vice president, chief financial officer in October 2007. Mr. Lambert served as senior vice president, chief financial officer of Quest Software, Inc., a publicly held developer and distributor of software products, from April 2005 until joining AMO. He previously served as senior vice president, finance of Quest Software, Inc. from November 2004 to April 2005. Before joining Quest, Mr. Lambert... View Full Profile

Michael J. Lambert

Top Competitors: EYE

View Detailed Competitors Chart

Insider Trends: EYE
Sentiment for EYE is POSITIVE
- 0M
- 2M
- 4M
- 6M
- Market Value of Insider Sales
- Market Value of Insider Purchases
Total dollar value of all insider purchases and sales over 12 months
View All Insider Sentiment

Insider Transactions: EYE

Date	Name	Shares	Transaction Type	Market Value
05/30/08	TRENARY CHARLES RUSSELL III	1,000	Planned Sale	$24,201.90
05/30/08	TRENARY CHARLES RUSSELL III	1,000	Sale	$24,201.90
05/30/08	TRENARY CHARLES RUSSELL III	1,000	Exercise of Stock Options	$8,990.00

View All Insider Activity

Ownership Breakdown : EYE

Large Block Holder Type	Number
Institutions	214.00
Mutual Fund	297.00
Other Major	11.00

Full Details

Indices : EYE

Symbol	Name	Last Trade	Change
$RUI.X	Russell 1000 Index	690.92	-0.56 -0.08%
$IDX	S&P 400 Midcap Index	—	——%

View all Indices that include EYE

Short Interest Volume: EYE

Data as of 6/10/08

Current Short Interest Shares	1.10 B
Current Short Interest Ratio	15.70
Float	60.48 M

Short Interest as % of Float	17.20
Average Daily Volume	710,000.00
Outstanding Shares	60.82 M

Full Details

SEC Filings: EYE

Accepted Date	Description
06/26/2008	SEC Filing: Annual Rpt Employee Plans
06/05/2008	SEC Filing: >= 5% Acquisition
06/04/2008	SEC Filing: Current Event

View all SEC Filings

Get Profile Details for:

- Help & Feedback

Market Movers

Related Resources

My Portfolios

AOL Real-Time Streaming Quotes

ADVANCED MEDICAL OPTICS INC

EYE

Stock price

18.71 -0.31 -1.63%

as of 01:05 PM EDT on 07/03/2008 in USD (NYSE Delay: 20 mins.)
Analyst Consensus
- Strong Buy
- Buy
- Hold
- Sell
- Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: EYE

Quote Search Search the Web Search

Live Updates:

Ticker

Dynamic view of the market

ADVANCED MEDICAL OPTICS INC

EYE

Stock price

Extended Hours

Analyst Consensus

ADVANCED MEDICAL OPTICS INC Profile

Key Executives: EYE

Top Competitors: EYE

Insider Trends: EYE

Insider Transactions: EYE

Ownership Breakdown : EYE

Indices : EYE

Short Interest Volume: EYE

SEC Filings: EYE

Quote Details

Classic Chart

Advanced Chart BETA

Real-Time Headlines

Message Boards

Profile

Earnings Analysis

Event Calendar

Financials

Market Movers

Related Resources

ADVANCED MEDICAL OPTICS INC

EYE

Stock price

Analyst Consensus

More in Money & Finance